Skip to main content
Monday, November 16, 2026Nov 16

On drug costs, modest steps follow Trump’s big promises

FILE - This Sept. 22, 2010 file photo shows bottles of the abortion-inducing drug RU-486 in Des Moines, Iowa. A new study published Tuesday, May 16, 2017 shows medical abortions done at home with online help and pills sent by mail appear to be just as safe as those done at a clinic. The research tracked 1,000 women in Ireland and Northern Ireland, who used a website to get abortion pills by mail and get around strict abortion laws. (AP Photo/Charlie Neibergall)
FILE - This Sept. 22, 2010 file photo shows bottles of the abortion-inducing drug RU-486 in Des Moines, Iowa. A new study published Tuesday, May 16, 2017 shows medical abortions done at home with online help and pills sent by mail appear to be just as safe as those done at a clinic. The research tracked 1,000 women in Ireland and Northern Ireland, who used a website to get abortion pills by mail and get around strict abortion laws. (AP Photo/Charlie Neibergall)

WASHINGTON (AP) – President Donald Trump makes big promises to reduce prescription drug costs, but his administration is gravitating to relatively modest steps such as letting Medicare patients share in manufacturer rebates.

Those ideas would represent tangible change and they have a realistic chance of being enacted. But it’s not like calling for Medicare to negotiate drug prices.

Skeptics say the overall approach is underwhelming, and Trump risks being seen as an ally of the powerful pharmaceutical industry, not its disrupter.

The White House Council of Economic Advisers has released a 30-page strategy for reducing drug costs, and it calls current policies “neither wise nor just.” The plan, outlined before Trump releases his new budget proposal Monday, focuses mainly on Medicare and Medicaid changes, along with ideas for speeding drug approvals and fostering competition.

“Despite promises to drastically lower prices the mix of proposed changes does not appear likely to do so, even though there are some constructive proposals,” said John Rother, CEO of the National Coalition on Health Care, an advocacy group whose members include consumer organizations, medical societies, hospitals and insurers.